{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:47:21Z","timestamp":1770500841765,"version":"3.49.0"},"reference-count":46,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[1992,3,1]],"date-time":"1992-03-01T00:00:00Z","timestamp":699408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World j. surg."],"published-print":{"date-parts":[[1992,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In patients with advanced or recurrent melanoma confined to a limb, hyperthermic isolated limb perfusion (ILP) with melphalan produces complete remission in 35\u201340% of cases and partial remission in a further 35\u201340%. Mild or moderate limb toxicity is usual, but severe toxic reactions in the limb sometimes occur. After preliminary reports suggested that cisplatin administered by ILP was even more effective than melphalan yet less toxic, a study was undertaken to further assess the value of hyperthermic ILP with cisplatin in the management of limb melanoma. Ten patients were treated. The procedure failed to eliminate melanoma in the limb in 5 of the 6 who received therapeutic ILPs for recurrent disease, and recurrence developed in 2 of the 4 patients who received prophylactic ILPs. Toxicity in the perfused limbs was unacceptably high, with 2 of the 10 patients having severe reactions, one necessitating amputation. We conclude from the results of this study and from a review of literature that neither cisplatin nor any other drug or drug combination so far used for ILP in melanoma patients achieves results which are clearly superior to those achieved with melphalan. Studies are currently in progress investigating double perfusion protocols, new strategies with regional hyperthermia, and the administration by ILP of biological response modifiers such as tumor necrosis factor and interferon. However, for the present, hyperthermic ILP with melphalan remains the treatment most likely to be successful in eliminating or controlling advanced or recurrent melanoma in a limb.<\/jats:p>","DOI":"10.1007\/bf02071525","type":"journal-article","created":{"date-parts":[[2005,8,13]],"date-time":"2005-08-13T21:02:16Z","timestamp":1123966936000},"page":"227-233","source":"Crossref","is-referenced-by-count":106,"title":["Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs"],"prefix":"10.1002","volume":"16","author":[{"given":"John F.","family":"Thompson","sequence":"first","affiliation":[{"name":"Sydney Melanoma Unit Royal Prince Alfred Hospital Missenden Road 2050 Camperdown New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark P.","family":"Gianoutsos","sequence":"additional","affiliation":[{"name":"Sydney Melanoma Unit Royal Prince Alfred Hospital Missenden Road 2050 Camperdown New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1992,3]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-195810000-00009"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-196004000-00024"},{"key":"e_1_2_1_4_1","first-page":"171","volume-title":"Cutaneous Melanoma","author":"Krementz E.T.","year":"1985"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860201)57:3<416::AID-CNCR2820570304>3.0.CO;2-M"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880215)61:4<654::AID-CNCR2820610406>3.0.CO;2-V"},{"key":"e_1_2_1_7_1","first-page":"101","article-title":"Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future","volume":"14","author":"Kroon B.B.","year":"1988","journal-title":"Eur. J. Surg. Oncol."},{"key":"e_1_2_1_8_1","first-page":"510","article-title":"Results of 206 isolated limb perfusions for malignant melanoma","volume":"15","author":"Lejeune F.J.","year":"1989","journal-title":"Eur. J. Surg. Oncol."},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930420315"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1990.01410150039008"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890315)63:6<1092::AID-CNCR2820630609>3.0.CO;2-W"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-82025-0_40"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870315)59:6<1068::AID-CNCR2820590604>3.0.CO;2-I"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930350306"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(88)80140-5"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(82)90235-8"},{"key":"e_1_2_1_17_1","first-page":"16","article-title":"Local and regional therapy for metastatic melanoma","volume":"14","author":"Thompson J.F.","year":"1990","journal-title":"Cancer Forum"},{"key":"e_1_2_1_18_1","unstructured":"Lejeune F. Krementz E. Vaglini M.(study coordinators):Protocol\u2014EORTC Malignant Melanoma Cooperative Group North American Perfusion Group and WHO Collaborating Centres for evaluation of methods of diagnosis and treatment of melanoma: A randomized trial on prophylactic isolation perfusion for Stage I high risk (>1.5 mm thickness) malignant melanoma of the limbs. Commenced March 1984 (unpublished)."},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1819"},{"key":"e_1_2_1_20_1","first-page":"127","article-title":"Hyperthermic antiblastic perfusion with DTIC in stage IIIA \u2013 III AB melanoma of the extremities","volume":"13","author":"Vaglini M.","year":"1987","journal-title":"Eur. J. Surg. Oncol."},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1051\/ject\/1982146475"},{"key":"e_1_2_1_22_1","first-page":"238","article-title":"Regional isolated perfusion of high risk melanoma of the extremities with imidazole carboxamide","volume":"158","author":"Ariyan S.","year":"1984","journal-title":"Surg. Gynecol. Obstet."},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860515)57:10<1961::AID-CNCR2820571013>3.0.CO;2-O"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-199104000-00007"},{"key":"e_1_2_1_25_1","first-page":"294","article-title":"A phase I trial of hyperthermic isolation limb perfusion (HILP) using cisplatin (CDDP) for metastatic melanoma","volume":"10","author":"Coit D.G.","year":"1991","journal-title":"Proceedings of ASCO"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(89)90572-2"},{"key":"e_1_2_1_27_1","first-page":"34","article-title":"Evaluation of isolated perfusion with cisplatin for malignant melanoma of the limbs","volume":"4","author":"Neades G.T.","year":"1991","journal-title":"Reg. Cancer Treat."},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-2197.1975.tb05719.x"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930200103"},{"key":"e_1_2_1_30_1","first-page":"6","article-title":"Regional perfusion in the treatment of the extremity melanoma","volume":"4","author":"Binder J.","year":"1991","journal-title":"Reg. Cancer Treat."},{"key":"e_1_2_1_31_1","first-page":"1","volume-title":"International Advances in Surgical Oncology, Vol. 1","author":"McBride C.M.","year":"1978"},{"key":"e_1_2_1_32_1","first-page":"8","article-title":"Perfusion of melanoma: 133 isolated perfusions in 114 patients","volume":"18","author":"Golomb F.M.","year":"1976","journal-title":"Panminerva Med."},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-82025-0_44"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000215480"},{"key":"e_1_2_1_35_1","first-page":"27","article-title":"High dose of rTNF\u03b4 combined with rIFN\u2010\u03b3 and melphalan administered in isolation perfusion produce 88% of complete remissions in melanoma and sarcoma","volume":"4","author":"Lienard D.","year":"1991","journal-title":"Reg. Cancer Treat."},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0730-725X(88)90410-9"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930210110"},{"key":"e_1_2_1_38_1","first-page":"255","article-title":"Levels of cis\u2010platinum in hyperthermic isolated perfusion","volume":"2","author":"Hild P.","year":"1982","journal-title":"Anticancer Res."},{"key":"e_1_2_1_39_1","first-page":"3108","article-title":"Experimental hyperthermic isolation perfusion using cis\u2010diamminedichloroplatinum (II)","volume":"43","author":"Wile A.G.","year":"1983","journal-title":"Cancer Res."},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01655662"},{"key":"e_1_2_1_41_1","first-page":"335","volume-title":"Handbook of Medical Oncology","author":"Bonadonna G.","year":"1988"},{"key":"e_1_2_1_42_1","first-page":"314","volume-title":"Cancer Chemotherapy: Principles and Practice","author":"Averbuch S.D.","year":"1990"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO;2-#"},{"key":"e_1_2_1_44_1","first-page":"3944","article-title":"Selective lethal effect of supranormal temperatures on human neoplastic cells","volume":"36","author":"Giovanella B.C.","year":"1976","journal-title":"Cancer Res."},{"key":"e_1_2_1_45_1","first-page":"61","article-title":"Heat as an adjuvant in the treatment of advanced melanoma: An immune stimulant?","volume":"4","author":"Stehlin J.S.","year":"1988","journal-title":"Houston Med. J."},{"key":"e_1_2_1_46_1","first-page":"21","article-title":"Results of a double perfusion schedule with melphalan for patients with measurable melanoma of the extremities","volume":"4","author":"Klaase J.M.","year":"1991","journal-title":"Reg. Cancer Treat."},{"key":"e_1_2_1_47_1","first-page":"24","article-title":"Application of hyperthermia in regional isolation perfusion for melanoma","volume":"4","author":"Kroon B.B.R.","year":"1991","journal-title":"Reg. Cancer Treat."}],"container-title":["World Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02071525.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02071525\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1007\/BF02071525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T18:07:56Z","timestamp":1703700476000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1007\/BF02071525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992,3]]}},"alternative-id":["10.1007\/BF02071525"],"URL":"https:\/\/doi.org\/10.1007\/bf02071525","archive":["Portico"],"relation":{},"ISSN":["0364-2313","1432-2323"],"issn-type":[{"value":"0364-2313","type":"print"},{"value":"1432-2323","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,3]]}}}